Given the strong association of the isocitrate dehydrogenase 1 and 2 (IDH1/2) genes mutations with glioma patients survival, the 2016 WHO classification, which integrates both histological and molecular features, has introduced the distinction of IDH-wildtype (IDH-wt) or IDH-mutant (IDH-mut) in diffuse gliomas (Louis et al., 2016). The gene discussed is IDH1; the disease is central nervous system cancer.